Conmed FCF Margin
The Free Cash Flow Margin of Conmed (CNMD) as of Jul 22, 2026 is 10.98 %. In the previous year, Free Cash Flow Margin was 11.77 % — a change of -6.78% (lower).
Get this data via API
Financial Data API
FCF Margin
10.98 %
YoY
-6.78%
Last updated:
Free Cash Flow Margin of Conmed is 2026 10.98 % . Free Cash Flow Margin of Conmed was 2025 11.77 % . It decreases by -6.78% lower compared to the previous year.
Access this data via the Eulerpool API
Conmed Stock analysis
What does Conmed do? Conmed Corporation is a leading medical technology company that offers a wide range of surgical instruments and devices for the fields of gastroenterology, endoscopy, orthopedics, gynecology, and electro surgery. The company was founded in 1970 and is headquartered in Utica, New York.
The history of Conmed Corp began with the founding of Consolidated Medical Equipment, Inc. (CME) in 1970. The company initially started its business with the distribution of surgical instruments and devices for medical applications and quickly expanded in this field. In the 1980s, the company went public.
In the 1990s, the company changed its name to Conmed Corporation and expanded its activities into the field of electro surgery, which has since become a major growth driver for the company.
Today, Conmed Corp operates multiple manufacturing facilities worldwide and has sales offices in over 50 countries. The company is divided into four main business segments: gastroenterology, endoscopy, orthopedics, and electro surgery.
The gastroenterology segment includes products for the diagnosis and treatment of gastrointestinal disorders, such as endoscopes, biopsy instruments, dilation balloons, trocars, and shears.
In the endoscopy segment, Conmed Corp offers products for the diagnosis and treatment of digestive tract disorders, including endoscopes, biopsy instruments, dilation balloons, trocars, and shears.
The orthopedics segment includes a wide range of surgical instruments and devices for the treatment of musculoskeletal disorders, including implants, bandages, bone plates, intramedullary nails, and others.
Finally, the electro surgery segment is the fastest-growing segment of Conmed Corp and includes a wide range of devices for precision surgery, including electrocautery, electro surgery, endoscopy, and laparoscopy devices.
Conmed Corp aims to develop innovative medical technologies that meet the needs of patients and healthcare professionals. The company places great emphasis on producing high-quality products that are reliable and safe.
Conmed Corp is a successful company that continues to evolve and expand its product range to meet the rapidly evolving needs of the medical community. Conmed is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Conmed stock
Free Cash Flow Margin of Conmed is 10.98 % in 2026.
Access this data via the Eulerpool API
Margins — Conmed
All Key Metrics — Conmed
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth